- Home
- Publications
- Publication Search
- Publication Details
Title
Fevipiprant in the treatment of asthma
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 27, Issue 2, Pages 199-207
Publisher
Informa UK Limited
Online
2018-01-24
DOI
10.1080/13543784.2018.1432592
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Associations in asthma between quantitative computed tomography and bronchial biopsy-derived airway remodelling
- (2017) Rachid Berair et al. EUROPEAN RESPIRATORY JOURNAL
- Fevipiprant, an oral prostaglandin DP2receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids
- (2017) Eric D. Bateman et al. EUROPEAN RESPIRATORY JOURNAL
- Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial
- (2017) Peter G Gibson et al. LANCET
- KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma
- (2017) Katherine N. Cahill et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma
- (2017) Parameswaran Nair et al. NEW ENGLAND JOURNAL OF MEDICINE
- Severe and Difficult-to-Treat Asthma in Adults
- (2017) Elliot Israel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tezepelumab in Adults with Uncontrolled Asthma
- (2017) Jonathan Corren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
- (2016) Eugene R Bleecker et al. LANCET
- Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
- (2016) Sally Wenzel et al. LANCET
- Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
- (2016) J Mark FitzGerald et al. LANCET
- The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma
- (2016) Veit J. Erpenbeck et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry
- (2016) Joan Sweeney et al. THORAX
- Fevipiprant, a prostaglandin D 2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial
- (2016) Sherif Gonem et al. Lancet Respiratory Medicine
- Airway Remodelling in Asthma: From Benchside to Clinical Practice
- (2016) Céline Bergeron et al. Canadian Respiratory Journal
- Asthma phenotypes and the use of biologic medications in asthma and allergic disease: The next steps toward personalized care
- (2015) Merritt L. Fajt et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The immunology of asthma
- (2015) Bart N Lambrecht et al. NATURE IMMUNOLOGY
- Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment
- (2015) Ian P. Hall et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
- (2015) Mario Castro et al. Lancet Respiratory Medicine
- Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459
- (2014) R. Pettipher et al. ALLERGY
- Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics
- (2014) Z. Diamant et al. CLINICAL AND EXPERIMENTAL ALLERGY
- Safety and Efficacy Of ARRY-502, a Potent, Selective, Oral CRTh2 Antagonist, In Patients With Mild To Moderate Th2-Driven Asthma
- (2014) Sally E. Wenzel et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells
- (2014) Luzheng Xue et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
- (2014) Elisabeth H. Bel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
- (2014) Hector G. Ortega et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression of DP2 (CRTh2), a Prostaglandin D2 Receptor, in Human Mast Cells
- (2014) Tae Chul Moon et al. PLoS One
- Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study
- (2014) Mario Castro et al. Lancet Respiratory Medicine
- Factors Associated With Poor Asthma Control in the Behavioral Risk Factor Surveillance System (BRFSS) Asthma Call-Back Survey 2009
- (2013) Joseph Espiritu CHEST
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
- (2013) K. F. Chung et al. EUROPEAN RESPIRATORY JOURNAL
- Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis
- (2013) Wendy C. Moore et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD
- (2013) Mika J. Mäkelä et al. RESPIRATORY MEDICINE
- Severe asthma: from characteristics to phenotypes to endotypes
- (2012) S. Wenzel CLINICAL AND EXPERIMENTAL ALLERGY
- Transcript profiling of CD16-positive monocytes reveals a unique molecular fingerprint
- (2012) Marion Frankenberger et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459
- (2012) D. Singh et al. EUROPEAN RESPIRATORY JOURNAL
- Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients
- (2012) William W. Busse et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
- (2012) Ian D Pavord et al. LANCET
- Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets
- (2011) K. L. Wong et al. BLOOD
- A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma
- (2011) N. Barnes et al. CLINICAL AND EXPERIMENTAL ALLERGY
- Effectiveness and Safety of Bronchial Thermoplasty in the Treatment of Severe Asthma
- (2009) Mario Castro et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Transcriptional profiling reveals developmental relationship and distinct biological functions of CD16+ and CD16- monocyte subsets
- (2009) Petronela Ancuta et al. BMC GENOMICS
- Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
- (2009) Pranabashis Haldar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cluster Analysis and Clinical Asthma Phenotypes
- (2008) Pranab Haldar et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now